Physician profile
Alain Bouchard
NPI 1659336790
$13,020.87
in general payments reported to CMS, 2019-2025
30 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,433 · 2020: $163 · 2021: $51.09 · 2022: $6,328 · 2023: $1,770 · 2024: $582 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457 · Travel and Lodging: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.56 |
| Travel and Lodging | $1,589.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,785.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,713.19 | 2019-2025 | Leqvio |
| Boston Scientific Corporation | $1,697.88 | 2019-2023 | Watchman Access System, Watchman Flx |
| Janssen Research & Development, LLC | $1,141.88 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $229.29 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $227.98 | 2019-2024 | Repatha |
| Abbott Laboratories | $188.00 | 2019-2021 | |
| Edwards Lifesciences Corporation | $167.38 | 2020-2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.25 | 2019-2025 | Jardiance |
| Medtronic, INC. | $90.93 | 2024 | Selectsecure |
| Novo Nordisk INC | $69.79 | 2025 | Wegovy |
| Amarin Pharma, INC. | $59.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $58.46 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $55.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.30 | 2020-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.08 | 2019 | |
| Scpharmaceuticals INC. | $43.40 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $39.52 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $37.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.88 | 2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $24.34 | 2023 | Uptravi |
| Stryker Corporation | $23.27 | 2025 | Artix Mt |
| Lundbeck LLC | $22.22 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.92 | 2025 | Amvuttra |
| Astellas Pharma US INC | $19.90 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.59 | 2019 | |
| Cardiovascular Systems INC. | $13.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.67 | 2019 | |
| United Therapeutics Corporation | $5.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alain Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.